Remote patient monitoring for chronic heart failure in France: When an innovative funding program (ETAPES) meets an innovative solution (Satelia® Cardio)

N Pages, F Picard, F Barritault, W Amara, S Lafitte, P Maribas, P Abassade, J Ph Labarre, R Boulestreau, H Chaouky, M Abdennadher, H Lemieux, R Lasserre, C Bedel, L Betito, S Nisse-Durgeat, B Diebold, N Pages, F Picard, F Barritault, W Amara, S Lafitte, P Maribas, P Abassade, J Ph Labarre, R Boulestreau, H Chaouky, M Abdennadher, H Lemieux, R Lasserre, C Bedel, L Betito, S Nisse-Durgeat, B Diebold

Abstract

Introduction: Remote patient monitoring (RPM) is a telehealth activity to collect and analyze patient health or medical data. Its use has expanded in the past decade and has improved medical outcomes and care management of non-communicable chronic diseases. However, implementation of RPM into routine clinical activities has been limited. The objective of this study was to describe the French funding program for RPM (known as ETAPES) and one of the RPM solution providers (Satelia®) dedicated to chronic heart failure (CHF).

Methods: A descriptive assessment of both the ETAPES funding program and Satelia® RPM solution was conducted. Data were collected from official legal documents and information that was publicly available online from the French Ministry of Health.

Results and discussion: ETAPES was formally created in 2016 based on previous legislation pertaining to the national health insurance funding strategy. However, it only started to operate in 2018. Patients with CHF were only eligible if they were at medium or high risk of re-hospitalization with a New York Heart Association (NYHA) score superior or equal to two and a BNP>100 pg/ml or NT pro BNP>1000 pg/ml. Medical monitoring was supported through the therapeutic education of a patient on the RPM model of care with a minimum of three training sessions during the first six months. The use of Satelia® Cardio is noteworthy since it relies only on symptomatic monitoring through which the patient manually reports their information by answering a simple questionnaire on a regular basis and does not rely on any connected devices.

Conclusion: Innovative funding programs and solutions for RPM need real-world evaluation in the future.

Keywords: Chronic heart failure; health funding; remote patient monitoring; telehealth; telemedicine.

© The Author(s) 2022.

Figures

Figure 1.
Figure 1.
Satelia® doctor interface for the remote patient monitoring of chronic heart failure in France.
Figure 2.
Figure 2.
Satelia® patient interface for the remote patient monitoring of chronic heart failure in France.

References

    1. Farias FAC, Dagostini CM, Bicca YA, et al. Remote patient monitoring: a systematic review. Telemed J E Health 2020; 26: 576–583.
    1. Taylor ML, Thomas EE, Snoswell CL, et al. Does remote patient monitoring reduce acute care use? A systematic review. BMJ Open 2021; 11: e040232.
    1. Bashi N, Karunanithi M, Fatehi F, et al. Remote monitoring of patients with heart failure: an overview of systematic reviews. J Med Internet Res 2017; 19: e18.
    1. Andrès E, Talha S, Zulfiqar AA, et al. Current research and new perspectives of telemedicine in chronic heart failure: narrative review and points of interest for the clinician. J Clin Med 2018; 7: 544.
    1. Varma N, Love CJ, Michalski J, et al. TRUST investigators. Alert-based ICD follow-up: a model of digitally driven remote patient monitoring. JACC Clin Electrophysiol 2021; 7(8): 976–987.
    1. Versteeg H, Timmermans I, Widdershoven J, et al. Effect of remote monitoring on patient-reported outcomes in European heart failure patients with an implantable cardioverter-defibrillator: primary results of the REMOTE-CIED randomized trial. Europace 2019; 21: 1360–1368.
    1. Hindricks G, Varma N, Kacet S, et al. Daily remote monitoring of implantable cardioverter-defibrillators: insights from the pooled patient-level data from three randomized controlled trials (IN-TIME, ECOST, TRUST). Eur Heart J 2017; 38: 1749–1755.
    1. Avram R, Ramsis M, Cristal AD, et al.. Validation of an algorithm for continuous monitoring of atrial fibrillation using a consumer smartwatch. Heart Rhythm 2021; 18(9): 1482–1490.
    1. Gawałko M, Duncker D, Manninger M, et al. The European TeleCheck-AF project on remote app-based management of atrial fibrillation during the COVID-19 pandemic: centre and patient experiences. Europace 2021; 23: 1003–1015.
    1. Pluymaekers NAHA, van der Velden RMJ, Hermans ANL, et al. On-demand mobile health infrastructure for remote rhythm monitoring within a wait-and-see strategy for recent-onset atrial fibrillation: TeleWAS-AF. Cardiology 2021; 146: 392–396.
    1. Koehler J, Stengel A, Hofmann T, et al. Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the telemedical interventional monitoring in heart failure (TIM-HF) study. Eur J Heart Fail 2021; 23: 186–194.
    1. Winkler S, Koehler K, Prescher S, et al. Is 24/7 remote patient management in heart failure necessary? Results of the telemedical emergency service used in the TIM-HF and in the TIM-HF2 trials. ESC Heart Fail 2021; 8(5): 3613–3620.
    1. Inglis SC, Clark RA, Dierckx R, et al. Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database Syst Rev 2015; 10: CD007228.
    1. Galinier M, Roubille F, Berdague P, et al. Telemonitoring versus standard care in heart failure: a randomised multicentre trial. Eur J Heart Fail 2020; 22: 985–994.
    1. Le Douarin Y, Traversino Y, Graciet A, et al. participants of Giens XXXV Round Table Health, economy. Telemonitoring and experimentation in telemedicine for the improvement of healthcare pathways (ETAPES program). Sustainability beyond 2021: what type of organisational model and funding should be used? Therapie. 2020;75:43–56.
    1. Ministère des Solidarités et de la Santé. Liste des solutions techniques déclarées conformes au cadre règlementaire de la télésurveillance. Accessed at: (Last accessed on 6 August 2021)
    1. Kuhn E, Rogge A, Schreyer K, et al. Apps auf Rezept in der Arztpraxis, aber wie? Fallbasierter Problemaufriss medizinethischer Implikationen bei der Nutzung von DiGA [Apps on Prescription in the Medical Office, but how? A Case-based Problem Outline of Medical-ethical Implications of DHA Usage]. Gesundheitswesen. 2021 May 6. German.
    1. Düvel JA, Gensorowsky D, Hasemann L, et al. Lösungsansätze für den Zugang digitaler Gesundheitsanwendungen zur Gesetzlichen Krankenversicherung: eine qualitative Studie [Digital Health Applications: A Qualitative Study of Approaches to Improve Access to Statutory Health Insurance]. Gesundheitswesen. 2021 Feb 26. German.
    1. Centers for Medicare & Medicaid Services (CMS), HHS. Medicare and Medicaid Programs; CY 2019 Home Health Prospective Payment System Rate Update and CY 2020 Case-Mix Adjustment Methodology Refinements; Home Health Value-Based Purchasing Model; Home Health Quality Reporting Requirements; Home Infusion Therapy Requirements; and Training Requirements for Surveyors of National Accrediting Organizations. Final rule with comment period. Fed Regist 2018; 83: 56406–56638.
    1. Centers for Medicare and Medicaid Services. List of Telehealth Services. Accessed at: (Last accessed on 6 August 2021)
    1. Vanier A, Oort FJ, McClimans L, et al. Response Shift - in Sync Working Group. Response shift in patient-reported outcomes: definition, theory, and a revised model. Qual Life Res. 2021; 30(12): 3309–3322.
    1. Van Spall HGC, Rahman T, Mytton O, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur J Heart Fail 2017; 19: 1427–1443.
    1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol (Engl Ed) 2016; 69: 1167. English, Spanish. doi: 10.1016/j.rec.2016.11.005. Erratum in: Rev Esp Cardiol (Engl Ed). 2017 Apr;70(4):309-310.
    1. Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21: 1169–1186.
    1. Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet 2018; 392: 1047–1057.
    1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599–3726.
    1. Journal Officiel de la République Française n°0315 du 30 Décembre 2020. Texte n°72. Arrêté du 23 décembre 2020 portant cahiers des charges des expérimentations relatives à la prise en charge par télésurveillance mis en œuvre sur le fondement de l’article 54 de la loi n° 2017-1836 de financement de la sécurité sociale pour 2018.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi